Association between PD-L1 expression with EGFR, ALK, and ROS1 driver oncogene mutations in non-small cell lung cancer

Simple item page
dc.contributor.authorOnur, Den_US
dc.contributor.author?lhan, Yen_US
dc.contributor.authorBüge, Ö.en_US
dc.date.accessioned2025-06-19T05:55:13Z
dc.date.available2025-06-19T05:55:13Z
dc.date.issued2025-03
dc.description.abstractBackground: Driver mutations and immunological expressions have gained importance in recent years for targeted therapies and immunotherapies of nonsmall cell lung cancer (NSCLC). Aims: This study examined the association between PD?L1 expression and ALK, ROS1, and EGFR driver oncogene mutations in patients with NSCLC. Materials and Methods: A total of 501 NSCLC patients were included for analysis. Immunohistochemistry was performed with a PD?L1 clone 22c3. EGFR mutations were detected by PCR. ALK and ROS1 rearrangement analysis was performed with FISH. Results: There was a highly statistically significant difference between PD?L1 expression and EGFR mutation. PD?L1 expression was higher in the EGFR wild?type than in mutated EGFR (P = 0.0002). There was no relationship between PD?L1 expression and ALK and ROS1 mutations (P = 0.8899, P = 0.2512, respectively). PD?L1 expression was higher in nonadenocarcinomas (non?AC) than in adenocarcinomas (AC) (P = 0.0438). The ALK rearrangement and EGFR mutations were higher in ACs (P = 0.0073, P = 0.0012, respectively). ALK, ROS1 rearrangements, and EGFR mutations were higher in nonsmokers (P<0.05). EGFR mutations were detected more frequently in females than males (P = 0.001). There was no relationship between gender and ALK, ROS1, and PD?L1 (P > 0.05). The prevalence of EGFR, ALK, and ROS1 driver mutations in the Turkish population was 9.3%, 5.3%, and 2.4%, respectively. Conclusions: In conclusion, PD?L1 expression and mutated EGFR status have a highly negative association. PD?L1 expression was higher in EGFR wild?type patients. Therefore, it shows that the opportunity to receive PD?L1?related treatment may be higher in these patients. We think that PD?L1 immunohistochemical evaluation will increase the clinical predictive importance in EGFR wild?type cases.en_US
dc.identifier.affiliationsDepartment of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul; Department of Pathology, Cerrahpa?a Medical Faculty, Istanbul University?Cerrahpa?a, Istanbul, Turkeyen_US
dc.identifier.affiliationsDepartment of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbulen_US
dc.identifier.affiliationsDepartment of Pathology, Cerrahpa?a Medical Faculty, Istanbul University?Cerrahpa?a, Istanbul, Turkeyen_US
dc.identifier.citationOnur D, ?lhan Y, Büge Ö.. Association between PD-L1 expression with EGFR, ALK, and ROS1 driver oncogene mutations in non-small cell lung cancer. Indian Journal of Pathology & Microbiology. 2025 Mar; 68(1): 36-41en_US
dc.identifier.issn0377-4929
dc.identifier.issn0974-5130
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/249963
dc.languageenen_US
dc.publisherWolters Kluwer - Medknowen_US
dc.relation.issuenumber1en_US
dc.relation.volume68en_US
dc.source.urihttps://doi.org/10.4103/ijpm.ijpm_939_23en_US
dc.subjectALKen_US
dc.subjectEGFRen_US
dc.subjectimmunohistochemistryen_US
dc.subjectNSCLCen_US
dc.subjectPD?L1en_US
dc.subjectROS1en_US
dc.titleAssociation between PD-L1 expression with EGFR, ALK, and ROS1 driver oncogene mutations in non-small cell lung canceren_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
IJPM2025v68n1p36.pdf
Size:
775.14 KB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Pathology & Microbiology